Newsletter

Hi and good morning,

Today we are going to be focusing on a Nasdaq profile that’s been receiving major attention for its news in recent months. As this is a morning profile we’re going to jump right in:

This Morning’s new profile is

CollabRx, Inc. (CLRX)

Website: www.collabrx.com

Quote: finance.yahoo.com/q?s=CLRX

CollabRx is a recognized leader in cloud-based expert systems to inform healthcare decision-making.

As a data analytics company, CLRX uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world’s knowledge on molecular medicine with specific insights from the nation’s top clinical experts.

CollabRx is a leading informatics company focused on the interpretation of complex molecular and genetic tests in cancer.

CollabRx uses information technology to aggregate and contextualize the world’s knowledge of genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of the greatest need: advanced cancers in patients who have effectively exhausted the standard of care.

The Company is partnered with some of the largest names in Healthcare:

• American Society of Clinical Oncology – Pioneered development of the initial CollabRx Therapy Finder
• College of American Pathologists – Facilitating patient access to CollabRx Therapy Finders for lung cancer, melanoma, and colorectal cancer
• University of Chicago Medical Center – CollabRx and the Thoracic Oncology program at the University of Chicago to collaborate on clinical cancer sequencing and interpretation
• The Jackson Laboratory – CollabRx to provide clinical interpretation of genetic sequencing-based tests
• Quest Diagnostics – CollabRx to provide annotation for new Quest Diagnostics next-gen sequencing test services for cancer
• Affymetrix 
• Life Technologies
• Cellnetix
• Cynvenio Biosystems
• Sengenics
• OncoDNA
• GeneInsight

Just a couple months back, CLRX entered into a Definitive Merger Agreement with Medytox Solutions, Inc. (MMMS).

Medytox currently owns and operates a diverse family of healthcare companies, including several clinical testing laboratories, an electronic medical records provider, a laboratory information systems company, and a medical billing company.

Look at these numbers: For the 12-months ended Dec 31, 2014, Medytox Solutions reported net revenue of 57.9Mln USD and income from operations of 15.7Mln USD, an increase of 38.3% and 8%, respectively, over the same 12-month period in 2013.

In the past year CLRX has seen some major swings… including a run from just .78 to a high of 2.74 within a period of less than a month.

It’s currently at .78 again and if it were to see a similar run back to those higher levels it could represent a run of over 250%.

I’m not saying I expect or even think such a run will occur; yet a bounce from these levels could be fun to watch.

Let’s take a quick look at the Indicators:

Short Term

Exponential Moving Average: Very Bullish

Fibonacci: Bullish

Low Analysis: Bullish

Stochastic: Bullish

Medium Term

Exponential Moving Average: Bullish

Moving Average Convergence/Divergence: Bullish

Long Term

Moving Average Convergence/Divergence: Very Bullish

High Analysis: Bullish

Now I should also mention that earlier this month, on June 5th, the Company “received a letter from The NASDAQ Stock Market LLC ("Nasdaq") stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing.”

See the full press release here:

CollabRx Announces Receipt of NASDAQ Notice of Noncompliance for Bid Price

If it does make a move towards previous levels we could be looking at something quite exciting.

So get started on researching CLRX immediately… we could be in for another big day ahead.

Remember, we always encourage you to do further research. Never take our word for it, read our disclaimer to see why, and of course always consult a professional.

Just because a situation looks great things can still go wrong and often do. The past is not always a good indication of what the future will bring. Be smart and protect yourself. 

Enjoy your morning,

Q

IMPORTANT NOTICE AND DISCLAIMER

This is a paid email ad. Do not base any investment or financial decisions upon any of the materials found in this publication or on our Website.

Please Note: Market 365 employees are not registered as financial advisors in any jurisdiction whatsoever.

Our full disclaimer is to be read and fully understood before using our site, or joining our email list. By viewing our website and/or reading our email newsletter you are agreeing to our full disclaimer which can be read at: http://www.qualityotc.com/disclaimer.php

The information contained on our website or in any of our newsletters is for informational purposes only, and is not intended to be advice, nor a recommendation and/or guidance for investment and/or financial decisions. In preparing our publications, we rely upon publicly available information including press releases, which we believe to be reliable, but have not verified. Our web site and our newsletter are services of Market 365, a media, marketing and ad firm that is engaged in the business of profiling companies for monetary compensation. All direct and third party compensation received has been disclosed in our newsletter and/or our website in accordance with section 1 7 ( b ) of the Securities Act of 1 9 3 3.

We have not been compensated for this email profile. We have not been compensated for the mention of CLRX or any other public company that may be discussed in this email. We do not own any shares or hold any positions in CLRX or any other public company mentioned in this email.